Navigation Links
WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
Date:11/21/2011

ignature of interest.  This should enable greater accuracy for discovery of biomarkers and decreased time to results," said Professor Jo Vandesompele, a professor in functional cancer genomics and applied bio-informatics at Belgium's Ghent University and recognized leader in the field of qPCR.

WaferGen's new strategy and organization changes will result in a reduction of approximately 24% of the Company's total workforce, which represents a $1.3 million annual reduction in operating expenses. The Company will take a one-time charge related to the reduction in force of approximately $400,000 in the fourth quarter of 2011.

RevenueRevenue for the third quarter ended September 30, 2011 was $89,000 compared to $633,000 for the third quarter ended September 30, 2010.  Revenue for the nine months ended September 30, 2011 was $485,000 compared to $1.5 million for the nine months ended September 30, 2010. The decrease is primarily due to decreases in sales of SmartChip Real-Time PCR Systems, Real-Time PCR Chip panels and Fee-for-Service, as well as first quarter sales of SmartSlide™ products (which the Company no longer markets).

Net Income/LossWaferGen reported net income attributable to common stockholders of $3.2 million, or $0.08 per share (basic), $0.03 per share (diluted) for the third quarter of 2011, compared to a net loss attributable to common stockholders of $5.7 million, or $(0.14) per share (basic and diluted) for third quarter 2010.  The Company reported a net loss attributable to common stockholders of $19.2 million, or $(0.46) per share (basic and diluted), compared to a loss attributable to common stockholders of $9.7 million, or $(0.27) (basic and diluted) for the same period in 2010.  The net loss attributable to common stockholders for the first nine months of 2011 includes non-cash charges to net income totaling $5.7 million resulting from new accounting entries related to the closing of the $30.6 mill
'/>"/>

SOURCE WaferGen Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. WaferGen Announces Delay in Reporting of Second Quarter 2011 Results
2. WaferGen Announces $30 Million Financing
3. WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing
4. WaferGen Announces General Availability of Quick-Turnaround SmartChip Custom Panels
5. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
6. WaferGen Corporate Presentation to be Webcast at Rodman and Renshaws 12th Annual Healthcare Conference
7. WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System
8. WaferGen Announces that University of Texas Southwestern Medical Center Demonstrates Utility of New SmartChip(TM) Nano-Dispenser with WaferGens SmartChip(TM) High-throughput Real-Time PCR System
9. WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Companys Scientific Advisory Board
10. WaferGen Closes on Private Financings of Approx. $6.2 Million
11. WaferGen to Present at the Rodman and Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues  ("BioLife" or ... 2015 Annual Meeting of Stockholders on May 4, 2015 ... for the Annual Meeting represents a change of more ...
(Date:12/24/2014)... 23, 2014 On Friday, December ... 83, the Omnibus and Continuing Resolution Appropriations Act ... hydrocephalus a condition eligible to receive funding through ... by the Department of Defense (DoD). The Hydrocephalus ... on Capitol Hill, is celebrating this victory for ...
(Date:12/24/2014)... Pipette.com announces their Holiday in the ... their #HolidayInTheLab pictures for a chance to win pipette-themed ... those struggling to think of a holiday gift for ... Lab Contest provides the ideal holiday presents. The #HolidayInTheLab ... pictures of their chemistree, holiday sweaters, as well as ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... PLYMOUTH MEETING, Pa. , Aug. 2 /PRNewswire-Asia-FirstCall/ -- BMP ... today announced,that the Company plans to release second quarter 2010 financial results on, ... , , ... a conference call at 5:00 pm ET on August 9, ...
... 2 Octapharma USA today announced the first ... Rush Hemophilia & Thrombophilia Center at Rush University Medical Center ... protein therapies in hematology, immune therapy, intensive care and emergency medicine. , ... Leonard A. Valentino, M.D. , ...
... LAUSANNE , Switzerland , August 2, 2010 ... sale of its Global Films,business to Bilcare AG, one of the world,s ... EUR100,million . The agreement brings together complimentary capabilities and,synergy,s of two ... , ...
Cached Biology Technology:BMP Sunstone to Report Second Quarter 2010 Financial Results 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6Bilcare AG to Acquire INEOS' Global Films Business for EUR100 Million 2Bilcare AG to Acquire INEOS' Global Films Business for EUR100 Million 3
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... shows how researchers can begin to distinguish the ,driver, mutations ... are a by-product of cancer cell development. The study also ... removed without killing human cells. Many cancer genomes are ... to be passengers mutations that don,t contribute to the ...
... CLEVELAND Ardiem Medical Inc. has obtained ... devices based on intellectual property developed at Case ... the Functional Electrical Stimulation (FES) Center in Cleveland. ... Medical, a medical devices manufacturer based in Indiana, ...
... , UTRECHT, The ... Match, the leading provider of high-performance search and match,software, today announced ... , has released an iPhone app for their JobStairs website that,uses ... largest,companies in Germany . Job seekers simply download the free ...
Cached Biology News:Sorting the drivers from the passengers in the cancer genome 2Sorting the drivers from the passengers in the cancer genome 3milch & zucker Takes ELISE Mobile With JobStairs iPhone App 2
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Request Info...
Biology Products: